Buscar
Mostrando ítems 1-5 de 5
Artículo
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
(BMC, 2018)
Background: Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive ...
Artículo
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma
(Nature publishing group, 2018)
Background: In the coBRIM study, cobimetinib plus vemurafenib (C þ V) significantly improved survival outcomes vs placebo and vemurafenib (P þ V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis ...
Artículo
2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary
(Springer, 2018)
Cancer of unknown primary (CUP) is defned as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original site have failed. They difer from other primary tumours in their ...
Artículo
SEOM clinical guideline for the management of malignant melanoma (2017)
(Springer Int Publ Ag, 2018)
All melanoma suspected patients must be con firmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be ...
Artículo
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
(Oxford University Press, 2018)
Background: Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), ...